NEUROCRINE BIOSCIENCES INC (NBIX)       108.25  -0.13 (-0.12%)

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

7 A-Rated Stocks to Buy for Less Than $25

These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.

Why Voyager Therapeutics Stock Is Sinking This Week

Investors are taking profits on this red-hot stock this week.

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results...

Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review

Sharp Tesla price cuts and some notable earnings were in focus.

Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal

Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.

VYGR stock jumps on licensing deal with Neurocrine (NASDAQ:VYGR)

Voyager Therapeutics (VYGR) added ~29% pre-market Monday announcing a licensing agreement with Neurocrine Biosciences (NBIX) for multiple gene therapies. Read the full story here.

Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 41st Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Pacific Time on...

FDA accepts Neurocrine's (NASDAQ:NBIX) application for movement disorder treatment

Neurocrine Biosciences (NBIX) said the U.S. FDA had accepted its supplemental new drug application for its treatment for Huntington's disease. Read more on the nod here.

Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and...

Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally

UnitedHealth is among medical stocks holding key support.

NBIX stock on watch as candidate for childhood epileptic disorder fails (NASDAQ:NBIX)

Neurocrine Biosciences (NBIX) announced that its investigational calcium channel blocker NBI-827104 failed in a Phase 2 trial in children with epileptic disorder. Read full story here.

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that investigational...

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, tod...

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical...

Interesting NBIX Put And Call Options For January 2023

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm

Neurodegenerative disorders could mean big bucks for some biotechs.

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor...

Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review

A mixed jobs report and heavy earnings swung stocks.

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting

SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA®...

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, tod...

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

/PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from...

Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat

The company raised its guidance for Ingrezza sales in 2022.

Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $376 MillionINGREZZA® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1...